Osteoid osteoma: can impedance levels in radiofrequency thermocoagulation predict recurrence?

Objective. To evaluate rise in impedance during percutaneous radiofrequency thermocoagulation (PRFTC) of osteoid osteomas as a predictor of local recurrence. Design and Patients. A prospective study of 23 patients (24 PRFTC procedures) with minimum of 2.25-year followup (average 3.3 years). Average age 19.6 years (range 4-44), sex ratio 15 : 8 (male : female), 16 nondiaphyseal, 7 diaphyseal. Results. In 19 procedures, an increase in impedance was measured-no recurrences have occurred in this group to date. In 5 procedures, no increase in impedance was seen (3 non-diaphyseal, 2 diaphyseal), and 1 recurrence has been seen in this group to date. This difference is statistically significant with a P value of .05.

Guidelines for histopathological specimen examination and diagnostic reporting of primary bone tumours.

This review is intended to provide histopathologists with guidelines for clinical assessment, specimen handling and diagnostic reporting of benign and malignant primary bone tumours. Information from radiology, surgical, oncology and other clinical colleagues involved in the diagnosis and treatment of primary bone tumours should be properly assessed before undertaking a structured approach to specimen handling and histological reporting. This ensures that the information needed for planning appropriate treatment of these complex tumours is provided. Consistency in diagnostic evaluation with respect to both terminology and report content facilitates liaison at multidisciplinary bone tumour meetings and collaboration between cancer units and networks, as well as providing a common database for audit of the clinical, radiological and pathological aspects of bone tumours.

Malignant variant of sclerosing perivascular epithelioid cell tumor arising in the adnexa.

The perivascular epithelioid cell family of tumors (PEComas) includes angiomyolipoma, lymphangioleiomyomatosis, clear-cell "sugar" tumor of the lung and a variety of extrapulmonary epithelioid and spindle-cell tumors referred to by various names. PEComas are now widely recognized histologically, and have been reported to occur at most anatomical sites, including the female genital tract. However, a distinctive variant of PEComa, designated "sclerosing PEComa," has only recently been described in the literature. All 13 of the cases of sclerosing PEComa reported thus far have been in women (mean age of 49 y), with a predilection for the retroperitoneum. Only one of the reported cases showed transition to a high-grade malignant phenotype. We report the first case of sclerosing PEComa arising in the uterine adnexa, with high-grade malignant transformation.

Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family.

PURPOSE: We have reported previously that intratumoral microvessel density (MVD) is a significant prognostic indicator of event-free survival in the Ewing's sarcoma family of tumors (ESFT). Here, the angiogenic growth factor expression profile and its relationship with MVD has been investigated in ESFT. EXPERIMENTAL DESIGN AND RESULTS: Using ESFT model systems, the potential of these factors as therapeutic targets has been evaluated. A significant correlation (P = 0.02) was observed between vascular endothelial growth factor (VEGF) expression and MVD, consistent with the hypothesis that VEGF regulates the development of microvessels in ESFT. There was no correlation between MVD and any of the other growth factors studied. All six ESFT cell lines studied produced and secreted VEGF; five of six cell lines also secreted placental growth factor, one cell line (A673) at high levels. Tumor conditioned medium induced proliferation of human umbilical vein endothelial cells. Expression of VEGF receptors Flt-1 and Flk-1/KDR was heterogeneous across the cell lines. Both receptor tyrosine kinase inhibitors SU6668 (targets Flk-1/KDR, platelet-derived growth factor receptor-beta, and fibroblast growth factor receptor 1) and SU5416 (targets Flk-1/KDR) as well as anti-VEGF agents rhuMAb-VEGF (bevacizumab) and VEGF Trap delayed s.c. growth of ESFT in mice compared with untreated groups: SU6668 (100 mg/kg/d), SU5416 (25 mg/kg/d), rhuMAb-VEGF (10 mg/kg twice weekly), and VEGF Trap (2.5 or 25 mg/kg twice weekly). CONCLUSIONS: These data suggest that VEGF is the single most important regulator of angiogenesis in ESFT and may be exploited for therapeutic advantage.